Literature DB >> 19090878

National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diuretics.

Elaine M Furmaga1, Francesca E Cunningham, William C Cushman, Diane Dong, Rong Jiang, Jan Basile, Lois A Katz, Gale H Rutan, Dan R Berlowitz, Vasilios Papademetriou, Peter A Glassman.   

Abstract

The authors sought to determine the prescribing practices of clinicians treating veterans with hypertension. A descriptive analysis was performed using a national pharmacy database of patients with a diagnosis of hypertension receiving antihypertensive medication in the fiscal years 2000 to 2006. Angiotensin-converting enzyme inhibitors were the most frequently prescribed antihypertensive class, with utilization increasing from 56.0% in fiscal year 2000 to 63.2% of patients in 2006. Utilization of thiazide-type diuretics increased from 31.9% of patients in fiscal year 2000 to 42.0% in 2006. When patient comorbidities were taken into consideration, 48.1% of patients defined as having uncomplicated hypertension had at least one prescription for a thiazide diuretic in fiscal year 2006. Utilization by monotherapy and combination therapy were also evaluated. The trends in utilization allowed for identification of areas in which a change in prescribing practices may improve blood pressure control and health outcomes in the Veterans Health Administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19090878      PMCID: PMC8673059          DOI: 10.1111/j.1751-7176.2008.00019.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  28 in total

1.  Inadequate management of blood pressure in a hypertensive population.

Authors:  D R Berlowitz; A S Ash; E C Hickey; R H Friedman; M Glickman; B Kader; M A Moskowitz
Journal:  N Engl J Med       Date:  1998-12-31       Impact factor: 91.245

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States.

Authors:  Y Richard Wang; G Caleb Alexander; Randall S Stafford
Journal:  Arch Intern Med       Date:  2007-01-22

4.  Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004.

Authors:  Jun Ma; Ky-Van Lee; Randall S Stafford
Journal:  Hypertension       Date:  2006-09-18       Impact factor: 10.190

5.  Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

Authors:  Kwok Leung Ong; Bernard M Y Cheung; Yu Bun Man; Chu Pak Lau; Karen S L Lam
Journal:  Hypertension       Date:  2006-12-11       Impact factor: 10.190

6.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

Authors:  Ihab Hajjar; Theodore A Kotchen
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

7.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

8.  Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents.

Authors:  B J Materson; D J Reda; W C Cushman; W G Henderson
Journal:  J Hum Hypertens       Date:  1995-10       Impact factor: 3.012

9.  Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  Hypertension       Date:  2003-08-18       Impact factor: 10.190

10.  Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

Authors:  S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

View more
  6 in total

1.  Hypertension control among newly treated patients before and after publication of the main ALLHAT results and JNC 7 guidelines.

Authors:  Marie Krousel-Wood; Paul Muntner; April Carson; Amanda H Anderson; Erin Delaune; William C Cushman; Jeffrey A Cutler; Linda B Piller; Gary A Goforth; Paul K Whelton
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-16       Impact factor: 3.738

2.  How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population-based study (2006-2014).

Authors:  Andrea L Schaffer; Sallie-Anne Pearson; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2016-07-28       Impact factor: 4.335

3.  Renewed interest in chlorthalidone: evidence from the Veterans Health Administration.

Authors:  Michael E Ernst; Brian C Lund
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08-30       Impact factor: 3.738

4.  Comparison of the Effect of Thiazide Diuretics and Other Antihypertensive Drugs on Central Blood Pressure: Cross-Sectional Analysis Among Nondiabetic Patients.

Authors:  Cristiano S Moura; Stella S Daskalopoulou; Linda E Levesque; Sasha Bernatsky; Michal Abrahamowicz; Meytal A Tsadok; Shadi Rajabi; Louise Pilote
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-07-20       Impact factor: 3.738

5.  Common secondary causes of resistant hypertension and rational for treatment.

Authors:  Charles Faselis; Michael Doumas; Vasilios Papademetriou
Journal:  Int J Hypertens       Date:  2011-03-02       Impact factor: 2.420

6.  A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.

Authors:  William C Cushman; George L Bakris; William B White; Michael A Weber; Domenic Sica; Andrew Roberts; Eric Lloyd; Stuart Kupfer
Journal:  J Hypertens       Date:  2018-04       Impact factor: 4.844

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.